The first full analysis of the H1N1 virus, published in Nature, shows it causes more lung damage in animals than seasonal flu. For two strains of virus tested, five times less was needed to cause the same damage as seasonal flu. Damage to the lungs increases the risk of pneumonia which is the commonest cause of complications, severe illness and death in flu epidemics.
I want to purchase this article: Katharine Sanderson,"Swine flu reaches into the lungs and gut", Nature News (2 July 2009) Price: US$8 In order to purchase this article you must be a registered user.
Price: US$8
In order to purchase this article you must be a registered user.
more revelations...
'Treatment Phase,' Course for 30M Brits | BBC | 2 July 2009
"Cases are doubling every week and on this trend we could see over 100,000 cases per day by the end of August." ...
The numbers are clear. Out of tens of thousands of infections in the UK, people are dying in their tens. Barely.
I suppose it's lucky we're descended from apes and not from obese ferrets, or we'd really be in trouble.
...we're descended from apes and not from obese ferrets...
Can we declare an official WHO Health Hysteria AlertTM yet?
No.
First, female employees must be sequestered;
Male model must be hired International Presenter™,
equipped with revised WHO script to acknowledge supreme leaders strep and CAP;
one 3m2 blackline anatomical drawing titled PNEUMONIA that illustrates
THERE IS NO DOOR BETWEEN NASAL CAVITY, MOUTH, AND LUNGS
and
WHERE LIVE MICRO-ORGANISMS DISPLACE AIR,
immune response also destroys "respiratory tissues";
and one 3m2 blackline technical drawing titled INTUBATION that illustrates
modern medicine,
THE ONGOING FAILURE TO INVENT RELIABLE CLINICAL TREATMENT OF ACUTE PNEUMONIAS,
increases probability of death
and professional panic. Diversity is the key to economic and political evolution.
Michael M. Patterson, PhD, "The Coming Influenza Pandemic: Lessons From the Past for the Future", JOMA. 2005
....In 1918, C.P. McConnell, DO,11 reported that the most effective treatment during the influenza pandemic was begun early in the onset of symptoms (within the first 24 hours) and consisted of carefully applied muscular relaxation and, most importantly, relaxation of the deep and extensive contractions of the deep spinal musculature and mobilization of the spine. These treatments would be repeated two or three times early in the course of the infection, along with traditional supportive measures such as hydration. During later influenza epidemics, such as the 1928-1929 and the 1936-1937 outbreaks, various lymphatic pump treatments and more attention to the cervical and upper thoracic regions were added to this recommended treatment protocol.12 These treatments, individualized to each patient's needs, were apparently the most commonly applied osteopathic medical procedures during the epidemics. It seems possible that the mechanisms of action of these treatments were to diminish somatic inputs from contracted muscles that had further stimulated the already overactive sympathetic system. This hyperreactivity exacerbated the counterproductive and deadly immune response. During the later phases of infection, osteopathic manipulative treatment (OMT) likely enhanced lymphatic drainage and encouraged appropriate immune response. While we have no controlled data on the effects of OMT on the pandemic influenza, several studies have shown the effects of OMT on somewhat related diseases. For example, Noll et al13 demonstrated that OMT given to elderly patients with pneumonia decreases medication use and hospital stay. More recently, Knott et al14 showed in a canine model that lymphatic treatment greatly increases lymph flow in the thoracic duct....
It seems possible that the mechanisms of action of these treatments were to diminish somatic inputs from contracted muscles that had further stimulated the already overactive sympathetic system. This hyperreactivity exacerbated the counterproductive and deadly immune response. During the later phases of infection, osteopathic manipulative treatment (OMT) likely enhanced lymphatic drainage and encouraged appropriate immune response.
While we have no controlled data on the effects of OMT on the pandemic influenza, several studies have shown the effects of OMT on somewhat related diseases. For example, Noll et al13 demonstrated that OMT given to elderly patients with pneumonia decreases medication use and hospital stay. More recently, Knott et al14 showed in a canine model that lymphatic treatment greatly increases lymph flow in the thoracic duct....
ht energyecon ;) Diversity is the key to economic and political evolution.
great news about lymph drainage, this is one really powerfully helpful therapy, invented in Austria.
good catch, MT! ~"When an inner situation is not made conscious, it appears outside as fate." Karl Jung~
then again, i'm sure he'd have been in a permanent, CNN-induced apoplectic state since March. Diversity is the key to economic and political evolution.
While waiting its dread mutation, look! CAP and Pneumonia severity index.
There are over a hundred microorganisms which can cause CAP. The most common types of microorganisms are different among different groups of people. Newborn infants, children, and adults are at risk for different spectrums of disease causing microorganisms. In addition, adults with chronic illnesses, who live in certain parts of the world, who reside in nursing homes, who have recently been treated with antibiotics, or who are alcoholics are at risk for unique infections. Even when aggressive measures are taken, a definite cause for pneumonia is only identified in half the cases.... Viruses cause 20% of CAP cases.
Viruses cause 20% of CAP cases.
knowing rummy is a part-owner of tamilflu does wonders for the immune system, lol! ~"When an inner situation is not made conscious, it appears outside as fate." Karl Jung~
Lawsuit puts flu-vaccine contract in doubt | Nature | 30 June 2009
A US office tasked with readying the country for influenza pandemics received an unpleasant surprise last week, when creditors filed a lawsuit intended to force one of its new grantees into bankruptcy. The lawsuit was filed the day before the Biomedical Advanced Research and Development Authority (BARDA) in Washington DC announced it had awarded a US$35-million contract to Protein Sciences, a biotechnology company in Meriden, Connecticut.
The lawsuit was filed the day before the Biomedical Advanced Research and Development Authority (BARDA) in Washington DC announced it had awarded a US$35-million contract to Protein Sciences, a biotechnology company in Meriden, Connecticut.
